Simulations Plus Releases ADMET Predictor™ Version 8.1
January 12 2017 - 8:30AM
Business Wire
Update streamlines key processes to
efficiently handle large data sets
Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of
simulation and modeling software and consulting services for
pharmaceutical discovery and development, today announced that it
has released Version 8.1 of its best-in-class ADMET Predictor™
molecular property prediction software.
Dr. David Miller, principal scientist and project leader for
ADMET Predictor, said: “This update builds upon the significant
refactoring of the version 8.0 release this past summer, with a
particular focus on enhancements to better serve research groups
working with large data sets. Key improvements include:
- 64-bit version is now available
- Optimization of spreadsheet and
model-building functions to improve efficiency
- New drug design features in the MedChem
Studio™ Module
- Rebuilt toxicity models that are more
broadly applicable
- Streamlined modeling using the ADMET
Modeler™ Module.”
John DiBella, vice president for marketing and sales for
Simulations Plus, added: “The feedback from scientists working with
ADMET Predictor 8.0 has been quite positive, as the stunning
visualization features and integration with MedChem Studio provides
them with a comprehensive platform for discovery research. We
achieved a 10% increase in the number of standalone ADMET Predictor
software units licensed in 1QFY17 versus the prior year, and the
improvements in this new release should result in further adoption,
as the ability to process large data sets quickly will help
scientists effectively communicate results to colleagues and lead
to informed decisions as projects progress.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
as filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170112005375/en/
Simulations Plus Investor
RelationsMs. Renee Bouche,
661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue,
651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024